Previous Article | Next Article 
Journal of Clinical Microbiology, August 2000, p. 3137-3138, Vol. 38, No. 8
0095-1137/00/$04.00+0
LETTERS TO THE EDITOR
Leukocyte Concentration in the Performance of the pp65
Antigenemia Assay
 |
LETTER |
One of the more controversial and debatable issues presently
confronting clinical virologists and infectious disease specialists is
the application of the cytomegalovirus antigenemia (CMV-Ag) assay (pp65
antigenemia assay) as a marker and predictor of CMV disease. For
example, recent reports have shown the CMV-Ag assay to be more accurate
than conventional DNA PCR or the more recent nucleic acid
sequence-based amplification (NASBA) as a predictor of CMV in patients
with AIDS (2). In a second comparison study, the CMV-Ag
assay was reported to be less accurate than the Digene Capture CM DNA
System (Digene), a nongenome amplification assay, as a predictor of CMV
disease in a similar (AIDS) patient population (13).
As recently pointed out by several researchers (13, 14),
differences in the purported efficacy of the CMV-Ag assay might reflect
such factors as antiviral management (prophylaxis against CMV versus no
prophylaxis), duration of patient observation (e.g., 8 versus 12 months), the number of CD4+ T-lymphocyte counts at patient
entry into a given study, the monitoring of CMV disease other than
retinitis, and/or the laboratory protocol used in the performance of
the CMV-Ag assay per se. Specifically, and perhaps most technically
important, data ascertained from CMV-Ag assay evaluation testing might
be skewed in relation to the input polymorphonuclear leukocyte (PMNL)
concentration utilized in the preparation of the cytospot.
Wattanamano and colleagues (13) compared three assays (the
CMV-Ag assay [Digene] and the AMPLICOR Qualitative PCR Test [Roche] as markers for the early detection of CMV infection in AIDS patients. Both the Digene and Roche assays were performed as described in the
manufacturers' specifications. However, the CMV-Ag assay was modified
from that of earlier protocols (1, 4), wherein single
cytospot preparations, each containing 150,000 polymorphonuclear leukocytes (PMNLs), were tested. In the Wattanamano et al. study, the
pp65 antigenemia assay was found to be slightly less sensitive than the
Digene assay (80% versus 85%), with both tests displaying equal
specificities. Both assays displayed equal predictive values.
In the performance of evaluation-comparison testing, researchers must
attempt to effect optimal assay parameters. Currently, most workers
prepare and test cytospot preparations containing a minimum of 200,000 PMNLs, which is recommended in two FDA-approved CMV-Ag assay kits
(12). The reporting of mean data obtained from duplicate
cytospot slide preparations also addresses any subtle or unrecognized
technical errors in cytospot preparation and/or immunostaining. Some
workers, furthermore, routinely utilize cytospot preparations
incorporating leukocyte input concentrations of 300,000 or 400,000 cells (3, 5, 6, 10). Lipson et al. (9) reported
improved sensitivity and increased pp65 positive cell counts by
utilizing an input population of 400,000 PMNLs/duplicate cytospot
preparation. Most recently, Landry and Ferguson (7) addressed the relevance of different leukocyte inocula concentrations in an evaluation-comparison study incorporating a new 2-h quantitative CMV-Ag assay (7). The significance of increased PMNL
inoculum concentrations in the detection of the CMV viremia in
immunocompromised patients has been described earlier in detail by
shell vial assay technology (8, 11).
In the evaluation-comparison study, failure to optimize one or another
diagnostic test has the potential of misdirecting the novice or even
confusing the experienced microbiologist. The readership should
appreciate the importance of the leukocyte input concentration in the
cytospot preparation as an important factor which may significantly impact interpretation of the CMV-Ag assay in evaluation-comparison testing, as well as in this assay's accuracy in clinical diagnostics.
| |
FOOTNOTES |
*
Phone: (212) 305-9118 Fax: (212)
305-8971 E-mail: montmor{at}aol.com
Ed. Note: The editor did not feel that a response was
necessary.
| |
REFERENCES |
| 1.
|
Bek, B.,
M. Boeckh,
J. Lepenies,
B. Bieniek,
K. Arasteh,
W. Heise,
K.-M. Deppermann,
G. Bornhoft,
M. Stoffler-Meilicke,
I. Schuller, and G. Hoffken.
1996.
High level sensitivity of quantitative pp65 cytomegalovirus (CMV) antigenemia assay for diagnosis of CMV disease in AIDS patients and follow-up.
J. Clin. Microbiol.
34:457-459[Abstract].
|
| 2.
|
Blank, B. S.,
P. L. Meenhorst,
J. W. Mulder,
G. J. Weverling,
H. Putter,
W. P. Willemien,
C. vanDuk,
P. Smits,
S. Lie-A-Ling,
P. Reiss, and J. M. A. Lange.
2000.
Value of different assays for detection of human cytomegalovirus (HCMV) in predicting the development of HCMV disease in human immunodeficiency virus-infected patients.
J. Clin. Microbiol.
38:563-569[Abstract/Free Full Text].
|
| 3.
|
Davoli, E. H.,
S. M. Lipson,
M. E. Match,
D. H. Sepp,
J. W. Morin, and D. M. Curley.
1999.
Evaluation of the PrimeCapture-R human cytomegalovirus (HCMV) DNA detection system for the identification of CMV in blood and cerebrospinal fluid.
J. Clin. Microbiol.
37:2587-2591[Abstract/Free Full Text].
|
| 4.
|
Dodt, K. K.,
P. H. Jacobson,
B. Hofmann,
C. Meyer,
H. J. Kolmos,
P. Skinhoj,
B. Norrild, and L. Mathiesen.
1997.
Development of cytomegalovirus (CMV) disease may be predicted in HIV infected patients by CMV polymerase chain reaction and the antigenemia test.
AIDS
11:F21-F28[CrossRef][Medline].
|
| 5.
|
Gerna, G.,
M. G. Revello,
E. Percivalle, and F. Morini.
1992.
Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for the optimal quantitation of human omegalovirus antigenemia.
J. Clin. Microbiol.
30:1232-1237[Abstract/Free Full Text].
|
| 6.
|
Kunse, S.,
P. Grossi,
W. Irish,
K. St. George,
C. Rinaldi,
J. Rakela, and J. Fund.
1999.
Cytomegalovirus pp65 antigenemia monitoring as a guide for preemptive therapy: a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients.
Transplantation
68:1125-1131[CrossRef][Medline].
|
| 7.
|
Landry, M. L., and D. Ferguson.
2000.
Two-hour cytomegalovirus pp65 antigenemia assay for rapid quantitation of cytomegalovirus in blood samples.
J. Clin. Microbiol.
38:427-428[Abstract/Free Full Text].
|
| 8.
|
Lipson, S. M.,
L. H. Falk, and S.-H. Lee.
1996.
Effect of leukocyte concentration and inoculum volume on the laboratory identification of cytomegalovirus in peripheral blood by the centrifugation culture-antigen detection methodology.
Arch. Pathol. Lab. Med.
120:53-56[Medline].
|
| 9.
|
Lipson, S. M.,
M. E. Match,
A. Toro, and D. H. Shepp.
1998.
Application of a standard cytomegalovirus antigenemia assay in the management of patients with AIDS.
Diagn. Microbiol. Infect. Dis.
32:75-79[CrossRef][Medline].
|
| 10.
|
Pannati, C. S.,
E. G. Kallas,
C. Mucdioli,
R. K. Rroland,
E. C. Ferrerir,
S. M. H. S. Bueno,
C. L. M. DoCanto,
L. S. Villas Boas, and R. Belfort, Jr.
1996.
Cytomegalovirus antigenemia in acquired immunodeficiency syndrome patients with untreated cytomegalovirus retinitis.
Am. J. Ophthalmol.
122:847-852[Medline].
|
| 11.
|
Reina, J.,
J. Saurina,
V. Fernandez-Baca,
I. Bianco, and M. Munar.
1998.
An increase of polymorphonuclear leukocytes inoculated on shell-vial culture increases the sensitivity of this assay in the detection of cytomegalovirus in the blood of immunocompromised patients.
Diagn. Microbiol. Infect. Dis.
31:425-428[CrossRef][Medline].
|
| 12.
|
St. George, K.,
M. J. Boyd,
S. M. Lipson,
D. Ferguson,
G. F. Cartmell,
L. H. Falk,
C. R. Rinaldo, and M. L. Landry.
2000.
Multisite trial comparing the cytomegalovirus (CMV) pp65 antigenemia test kits Biotest CMV Brite and Bartels/Argene CMV Antigenemia.
J. Clin. Microbiol.
38:1430-1433[Abstract/Free Full Text].
|
| 13.
|
Wattanamano, P.,
J. L. Clayton,
J. J. Kopicko,
P. Kissinger,
S. Elliot,
C. Jarrott,
S. Rangan, and M. A. Beilke.
2000.
Comparison of three assays for cytomegalovirus detection in AIDS patients at risk for retinitis.
J. Clin. Microbiol.
38:727-732[Abstract/Free Full Text].
|
| 14.
|
Weinberg, A.,
T. N. Hodges,
S. Li,
G. Cai, and M. R. Zamora.
2000.
Comparison of PCR, antigenemia assay, and rapid blood culture for detection and prevention of cytomegalovirus disease after lung transplantation.
J. Clin. Microbiol.
38:767-772.
|
| | | | |
Steven M. Lipson*
|
| | | | |
Phyllis Della-Latta
Clinical Microbiology Services
Columbia-Presbyterian Center
New York-Presbyterian Hospital
New York, NY 10032
|
Journal of Clinical Microbiology, August 2000, p. 3137-3138, Vol. 38, No. 8
0095-1137/00/$04.00+0
This article has been cited by other articles:
-
LaSala, P. R., Yarsa, J., Nguyen, D. V., Han, X. Y., Tarrand, J.
(2009). Evaluation of an Abbreviated Protocol for Cytomegalovirus pp65 Antigenemia Testing. Am J Clin Pathol
131: 526-531
[Abstract]
[Full Text]
